BTK and neoplasm: High concentrations of ibrutinib have also been described to decrease tumor cell adhesion in vitro [131]; however, when discussing BTK involvement in integrin inside-out activation, off-target kinase inhibition by this drug needs to be taken into account, and moreover, the reduction in baseline VLA-4 activation under ibrutinib can be overcome by antigen stimulation [7].